First, proteomics screening and statistical analysis show that blood biomarkers LGALS3BP, ACE, and POSTN effectively screen for cerebral amyloid depositions and clinically diagnose Alzheimer’s disease, but the theoretical basis is still lacking. The gene discussed is ACE; the disease is early-onset autosomal dominant Alzheimer disease.